Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.29 USD
-0.04 (-3.01%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $1.28 -0.01 (-0.78%) 7:44 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 81 - 100 ( 122 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Now Pursuing BLA for COVAXINTimeline Shift Moves Rating to Neutral $6PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Ocugen Gains Rights To Commercialize COVAXIN in Canada
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN EUA on Track to Be Filed in June; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Progress Continues, but COVAXIN''s EUA Filing Timeline Shifts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Shown to Be Efficacious Against Novel COVID-19 Variants
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Ground Conditions Weigh on 1Q21 Production Results; Technical Advisory Team Formed; Reiterate Buy; PT Lower
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
U.S. EUA Submission to Follow After Positive COVAXIN Interim Analysis
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Ocugen Hires SVP of Manufacturing Ahead of COVAXIN EUA Application
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Scored Robust Phase 3 Efficacy Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update - EUA Filing for COVAXIN in April, IND for OCU400 in 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Gains EUA in India, Could U.S. Be Next?
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z